New product: Tecartus (autologous anti-CD19-transduced CD3+ cells)

Tecartus a gene therapy containing autologous T cells genetically modified ex vivo is licensed for the treatment of adult patients with relapsed or refractory mantle cell lymphoma after two or more lines of systemic therapy including a Bruton's tyrosine kinase inhibitor.

electronic Medicines compendium